Article
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2009
Yu Jian, Kane Susan, Wu Jiong, Benedettini Elisa, Li Daiqiang, Reeves Cynthia, Innocenti Gregory, Wetzel Randy, Crosby Katherine, Becker Alison, Ferrante Michelle, Cheung Wan Cheung, Hong Xiqiang, Chirieac Lucian R, Sholl Lynette M, Haack Herbert, Smith Bradley L, Polakiewicz Roberto D, Tan Yi, Gu Ting-Lei, Loda Massimo, Zhou Xinmin, Comb Michael J
Abstract excerpt
PURPOSE: Activating mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are found in approximately 10% to 20% of non-small-cell lung cancer (NSCLC) patients and are associated with response to EGFR inhibitors. The most common NSCLC-associated EGFR mutations are deletions in exon 19 and L858R mutation in exon 21, together accounting for 90% of EGFR mutations. To develop a simple,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.